Wang X, Sun Y, Zhang Y, Zhi Z, Wang S, Li J, Sun Y, Sun Y (2024) Research trends and hotspots in clinical trials of migraine in the past 20 years: bibliometric analysis. Front Neurol 15:1430138. https://doi.org/10.3389/fneur.2024.1430138PMID: 39524909; PMCID: PMC11543406

Article  PubMed  PubMed Central  Google Scholar 

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia (2018);38(1):1-211. https://doi.org/10.1177/0333102417738202. PMID: 29368949

Lipton RB, Cohen JM, Galic M, Seminerio MJ, Yeung PP, Aycardi E, Bigal ME, Bibeau K, Buse DC (2021) Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study. Headache 61(4):662–672. https://doi.org/10.1111/head.14097PMID: 33891348; PMCID: PMC8251795

Article  PubMed  PubMed Central  Google Scholar 

Ferrari MD, Goadsby PJ, Burstein R, Kurth T, Ayata C, Charles A, Ashina M, van den Maagdenberg AMJM, Dodick DW, Migraine (2022) Nat Rev Dis Primers.;8(1):2. https://doi.org/10.1038/s41572-021-00328-4. PMID: 35027572

Peres MFP, Sacco S, Pozo-Rosich P, Tassorelli C, Ahmed F, Burstein R, Ashina S, Uluduz D, Husøy AK, Steiner TJ (2024) Migraine is the most disabling neurological disease among children and adolescents, and second after stroke among adults: A call to action. Cephalalgia.;44(8):3331024241267309. https://doi.org/10.1177/03331024241267309. PMID: 39197864

GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 (2018) Lancet Neurol.;17(11):954–976. https://doi.org/10.1016/S1474-4422(18)30322-3. Erratum in: Lancet Neurol. 2021;20(12):e7. doi: 10.1016/S1474-4422(21)00380-X. PMID: 30353868; PMCID: PMC6191530

Sakai F, Igarashi H (1997) Prevalence of migraine in Japan: a nationwide survey. Cephalalgia.;17(1):15–22. https://doi.org/10.1046/j.1468-2982.1997.1701015.x. PMID: 9051330

NovHeadache disorders (2024) How common are headaches? [WHO:, https://www.who.int/news-room/questions-and-answers/item/headache-disorders-how-co]. 2024 https://www.who.int/news-room/questions-and-answers/item/headache-disorders-how-co

Cohen F, Brooks CV, Sun D, Buse DC, Reed ML, Fanning KM, Lipton RB (2024) Prevalence and burden of migraine in the United States: A systematic review. Headache.;64(5):516–532. https://doi.org/10.1111/head.14709. Epub 2024 May 3. PMID: 38700185

Ray JC, Kapoor M, Stark RJ, Wang SJ, Bendtsen L, Matharu M, Hutton EJ (2021) Calcitonin gene related peptide in migraine: current therapeutics, future implications and potential off-target effects. J Neurol Neurosurg Psychiatry 92(12):1325–1334. https://doi.org/10.1136/jnnp-2020-324674Epub 2021 Jan 25. PMID: 33495299

Article  PubMed  Google Scholar 

Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: A randomized clinical trial. JAMA 319(19):1999–2008. https://doi.org/10.1001/jama.2018.4853PMID: 29800211; PMCID: PMC6583237

Article  CAS  PubMed  Google Scholar 

Saigoh K, Takeshima T, Nakai M, Shibasaki Y, Ishida M, Ning X, Barash S, Isogai Y, Koga N (2023) Fremanezumab for episodic migraine prevention in Japanese patients: subgroup analysis from two international trials. J Pain Res 16:1673–1682 PMID: 37223438; PMCID: PMC10202207

Article  CAS  PubMed  PubMed Central  Google Scholar 

Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, Grozinski-Wolff M, Yang R, Ma Y, Aycardi E (2017) Fremanezumab for the Preventive Treatment of Chronic Migraine. N Engl J Med.;377(22):2113–2122. https://doi.org/10.1056/NEJMoa1709038. PMID: 29171818

Garelja ML, Alexander TI, Bennie A, Nimick M, Petersen J, Walker CS, Hay DL (2024) Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors. Br J Pharmacol 181(1):142–161. https://doi.org/10.1111/bph.16218Epub 2023 Sep 14. PMID: 37580864; PMCID: PMC10840612

Article  CAS  PubMed  Google Scholar 

Scott LJ, Galcanezumab (2020) A Review in the Prevention of Migraine and Treatment of Episodic Cluster Headache. Drugs.;80(9):893–904. doi: 10.1007/s40265-020-01329-5. Erratum in: Drugs. 2020;80(13):1379. https://doi.org/10.1007/s40265-020-01371-3. PMID: 32504377

Lionetto L, Curto M, Cisale GY, Capi M, Cipolla F, Guglielmetti M, Martelletti P (2019) Fremanezumab for the preventive treatment of migraine in adults. Expert Rev Clin Pharmacol 12(8):741–748 Epub 2019 Jun 26. PMID: 31220963

Article  CAS  PubMed  Google Scholar 

Friedman DI, Cohen JM (2020) Fremanezumab: a disease-specific option for the preventive treatment of migraine, including difficult-to-treat migraine. Emerg Top Life Sci 4(2):179–190. https://doi.org/10.1042/ETLS20200018PMID: 32832978; PMCID: PMC7487173

Article  CAS  PubMed  PubMed Central  Google Scholar 

Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221. https://doi.org/10.1212/WNL.0000000000006640Epub 2018 Nov 16. PMID: 30446596; PMCID: PMC6329331

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tepper SJ, Sheikh HU, Dougherty CO, Nahas SJ, Winner PK, Karanam AK, Blumenfeld AM, Abdrabboh A, Rasmussen S, Weiss JL, Ailani J (2022) Erenumab dosage for migraine prevention: an evidence-based narrative review with recommendations. Headache 62(4):420–435. https://doi.org/10.1111/head.14266Epub 2022 Feb 9. PMID: 35137404

Article  PubMed  Google Scholar 

de Dios A, Pagès-Puigdemont N, Ojeda S, Riera P, Pelegrín R, Morollon N, Belvís R, Real J, Masip M (2025) Persistence, effectiveness, and tolerability of anti-calcitonin gene-related peptide monoclonal antibodies in patients with chronic migraine. Headache 65(1):24–34. https://doi.org/10.1111/head.14827Epub 2024 Sep 13. PMID: 39268992

Article  PubMed  Google Scholar 

Orlando B, Egeo G, Aurilia C, Fiorentini G, Barbanti P (2024) Calcitonin Gene-Related peptide monoclonal antibodies: key lessons from Real-World evidence. Brain Sci 14(9):948. https://doi.org/10.3390/brainsci14090948PMID: 39335442; PMCID: PMC11429799

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ohtani S, Watanabe N, Ihara K et al (2023) Real-world evidence of fremanezumab for treating migraine in Japan: a retrospective study. BMC Neurol 23:404. https://doi.org/10.1186/s12883-023-03449-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Suzuki S, Suzuki K, Shiina T, Haruyama Y, Hirata K (2023) Real-world experience with monthly and quarterly dosing of fremanezumab for the treatment of patients with migraine in Japan. Front Neurol 14:1220285. https://doi.org/10.3389/fneur.2023.1220285PMID: 37483436; PMCID: PMC10359132

Article  PubMed  PubMed Central  Google Scholar 

Vernieri F, Altamura C, Brunelli N, Costa CM, Aurilia C, Egeo G, Fofi L, Favoni V, Pierangeli G, Lovati C, Aguggia M, d’Onofrio F, Doretti A, Di Fiore P, Finocchi C, Rao R, Bono F, Ranieri A, Albanese M, Cevoli S, Barbanti P, GARLIT Study Group (2021) Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study). J Headache Pain 22(1):35. https://doi.org/10.1186/s10194-021-01247-1PMID: 33941080; PMCID: PMC8091153

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbanti P, Aurilia C, Egeo G, Proietti S, Torelli P, d’Onofrio F, Carnevale A, Tavani S, Orlando B, Fiorentini G, Colombo B, Filippi M, Bonassi S, Cevoli S, Italian Migraine Registry (I-GRAINE) study group (2024) Impact of multiple treatment cycles with anti-CGRP monoclonal antibodies on migraine course: focus on discontinuation periods. Insights from the multicenter, prospective, I-GRAINE study. J Neurol 271(5):2605–2614. https://doi.org/10.1007/s00415-024-12192-9Epub 2024 Feb 12. PMID: 38342785; PMCID: PMC11055727

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pavelic AR, Wöber C, Riederer F, Zebenholzer K (2022) Monoclonal antibodies against calcitonin Gene-Related peptide for migraine prophylaxis: A systematic review of Real-World data. Cells 12(1):143. https://doi.org/10.3390/cells12010143PMID: 36611935; PMCID: PMC9819019

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T, Ning X, Shima T, Ishida M, Iba K, Kondo H, Koga N (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092–1101. https://doi.org/10.1111/head.14169Epub 2021 Jul 29. PMID: 34324700; PMCID: PMC8456899

Article  PubMed  PubMed Central  Google Scholar 

Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X, Ishida M, Nagano K, Iba K, Kondo H, Koga N (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1102–1111. https://doi.org/10.1111/head.14178Epub 2021 Jul 29. PMID: 34323290; PMCID: PMC8457233

Article  PubMed  PubMed Central  Google Scholar 

Grazzi L, Giossi R, Montisano DA, Canella M, Marcosano M, Altamura C, Vernieri F (2024) Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain 25(1):14. https://doi.org/10.1186/s10194-024-01721-6PMID: 38308209; PMCID: PMC10836018

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barbanti P, Aurilia C, Egeo G, Torelli P, Proietti S, Cevoli S, Bonassi S, Italian Migraine Registry study group (2023) Late response to Anti-CGRP monoclonal antibodies in migraine: A multicenter prospective observational study. Neurology 101(11):482–488 Epub 2023 Apr 18. PMID: 37072224; PMCID: PMC10513886

Article  CAS  PubMed  PubMed Central  Google Scholar 

Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A, Raffaelli B, Reuter U, Neeb L (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study. Cephalalgia 42(4–5):291–301 Epub 2021 Oct 13. PMID: 34644203; PMCID: PMC8988456

Article  PubMed  Google Scholar